

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

**FORM 8-K**

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

January 25, 2010  
(Date of earliest event reported)

**LABORATORY CORPORATION OF  
AMERICA HOLDINGS**

---

(Exact Name of Registrant as Specified in its Charter)

**DELAWARE**

(State or other jurisdiction  
of Incorporation)

**1-11353**

(Commission  
File Number)

**13-3757370**

(I.R.S. Employer  
Identification No.)

**358 SOUTH MAIN STREET,  
BURLINGTON, NORTH CAROLINA**

(Address of principal executive offices)

**27215**

(Zip Code)

**336-229-1127**

(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. Regulation FD Disclosure

Summary information of the Company in connection with the presentation at the Jefferies 2010 Global Healthcare Services Conference on January 26, 2010.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Laboratory Corporation of America Holdings  
(Registrant)

Date: January 25, 2010

By: /s/F. Samuel Eberts III  
F. Samuel Eberts III, Chief Legal Officer  
and Secretary

---

# Jefferies 2010 Global Healthcare Services Conference

New York, NY


January 26, 2010



## Forward Looking Statement


This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors.

Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 2008, and subsequent SEC filings.



## Leading National Lab Provider

- Fastest growing national lab
- \$52 Billion market
- Clinical, Anatomic and Genomic Testing
- Serving clients in all 50 states and Canada
- Foremost clinical trials testing business



## Laboratory Testing




## Health Care Continuum

Source: Deloitte (OAML)

## Valuable Service


- Small component of total cost influences large percentage of clinical decisions
- Screening, early detection, and monitoring reduce downstream costs
- Companion diagnostics improve drug efficacy and reduce adverse drug effects

2008 Approximate US Health Care Spend \$2.4 Trillion



## Growth Drivers

- Aging population
- Industry consolidation
- Advances in genomics
- Pharmacogenomics / companion diagnostics
- Cost pressures




Source: CDC National Ambulatory Medical Care Survey and Company Estimates



## Opportunity to Take Share

- 5,100 independent labs
- High cost competitors




Source: Washington G-2, Laboratory Industry Report, January, 2009

## Diversified Payor Mix

- No customer > 9% of revenue
- Limited government exposure


**LabCorp U.S. Payor Mix**  
% of revenue, 2009 YTD



## Diversified Test Mix


- Esoteric 36% of revenue
- Goal of 40% in 3 – 5 years
- Higher priced business

**LabCorp U.S. Test Mix**  
% of revenue, 2009 YTD



## Scale and Scope

- National infrastructure
- Broad test offering
- Managed care contracts
- Economies of scale



- Patient Service Centers\*
- Primary LabCorp Testing Locations\*
- Esoteric Lab Locations  
(CET, CMBP, Dianon, Esoterix, Monogram Biosciences, NGI, OTS, US Labs, Viromed)

## Managed Care Relationships

- Exclusive national laboratory for UnitedHealthcare
- Sole national strategic partner for WellPoint
- Significant national plans recently renewed or extended on a multi-year basis, including WellPoint, Cigna and Humana
- Contracted with numerous local and regional anchor plans



## Scientific Leadership

- Introduction of new tests
- Acquisitions and licensing
- Collaborations with leading companies and academic institutions

Partner	Clinical Area
ARCA biopharma	Companion Diagnostics (CVD) (exclusive)
Celera Diagnostics	Breast Cancer
Duke University	Lung Cancer (exclusive)
Exact Sciences	Colon Cancer
Intema Ltd.	Prenatal Testing
Ipsogen	Molecular Diagnostics
Medco Health Solutions	Companion Diagnostics (Research)
OncoMethylome Sciences	Companion Diagnostics (Oncology) (exclusive)
Siemens Health Solutions	Companion Diagnostics (Oncology and CVD)
SmartGene	Bioinformatics Tools
Third Wave Technologies	Companion Diagnostics (CVD)
Vanda Pharmaceuticals	Companion Diagnostics (exclusive)
Veridex	Prostate Cancer
Yale University	Ovarian Cancer (exclusive)

## Standardized and Efficient Processes

- Standardized lab and billing IT systems
- Automation of pre-analytics
- Capacity rationalization
- Logistics optimization





## Our Focus


- Profitable revenue growth
- IT and client connectivity
- Continue scientific leadership
- Maintain price
- Control costs






## Profitable Revenue Growth

- Target specialty physicians with breadth of menu and services
- Educate payers and physicians on value of LabCorp testing
- Leverage assets from Monogram acquisition
- Continue to improve patient experience



## IT and Client Connectivity

- Enhance online services and analytic tools
- *LabCorp Inside the Box* for superior connectivity
- Improve Patient Experience through:
  - Automated PSC workflow
  - Patient access via PHRs, online appointments
  - Enterprise services including VoIP
- Continue “open platform” strategy to maximize options for users



## Continue Scientific Leadership

- Increase esoteric testing
- Grow and enhance offerings in personalized medicine:
  - Expand outcome improvement programs
  - Develop and commercialize companion diagnostics



## Increase Esoteric Testing

- Introduction of new tests
- Acquisitions and licensing
- Collaborations with academic institutions

### New Tests Include:

BRAF Gene Mutation Detection

EGRF Mutation Analysis for Nonsmall-Cell Lung Cancer

HERmark for Breast Cancer

Warfarin (P450 2C9 and VKORC1)

Clopidogrel CYP2C19 Genotyping

H1N1 – Flu Testing

Integrase – HIV Genotyping (GenoSure) and HIV Phenotyping (PhenoSense)

Enhanced Trofile

### Collaborations Include:


Duke University

National Jewish Health

Yale University

## Expand Outcomes Improvement

- Litholink kidney stone
- CKD
- Continual development of valuable programs



## Develop and Commercialize Companion Diagnostics

- Invest in clinical trials
- Relationships with biotech and pharma companies
- Promote key tests
  - K-RAS
  - HLA-B\* 5701
  - BRAF Gene Mutation Detection
  - EGRF Mutation Analysis
  - CYP 450 2C19
- Monogram Biosciences
  - Trofile
  - PhenoSense, PhenoSense GT
  - HERmark

**“K-RAS testing should be routinely conducted in all colorectal cancer patients immediately after diagnosis to ensure the best treatment strategies for the individual Patient”**

– Dr. Eric Van Cutsem, presenter at the June 2008 American Society of Clinical Oncology meeting

### **FDA recommends genetic screening prior to treatment with Abacavir**

ROCKVILLE, Md -- July 24, 2008 -- The US Food and Drug Administration (FDA) has issued an alert regarding serious, and sometimes fatal, hypersensitivity reactions (HSRs) caused by abacavir (Ziagen) therapy in patients with a particular human leukocyte antigen (HLA) allele, HLA-B\* 5701.

Genetic tests for HLA-B\*5701 are already available, and all patients should be screened for the HLA-B\*5701 allele before starting or restarting treatment with abacavir or abacavir-containing medications.

**“FDA has approved the expanded use of Selzentry... to include adult patients with CCR5-tropic HIV-1 virus who are starting treatment for the first time.”**

- ViiV Healthcare Press Release, November 20th, 2009

## Maintain Price

- Managed care stability; offsets 1.9% Medicare rate decrease
- Focus on high-value tests
- Promote outcome improvement

LithoLink Laboratory Reporting System™  
**Patient Results Report**

PATIENT: **Sample, Patient**      DATE OF BIRTH: **03/29/1953**      PHYSICIAN: **Test, Physician**

Values larger, bolder and more towards red indicate increasing risk for kidney stone formation.

**Summary Stone Risk Factors**

SAMPLE ID: **5189570**      PATIENT COLLECTION DATE: **06/04/2006**

ANALYTE	DECREASED RISK	INCREASING RISK FOR STONE FORMATION
Urine Volume (liters/day)		● <b>1.46</b>
SS CaOx	● 5.87	
Urine Calcium (mg/dl)	● 101	
Urine Oxalate (mg/dl)	● 33	
Urine Citrate (mg/dl)		● <b>358</b>
SS CaP	● 0.56	
24 Hour Urine pH	● 6.100	
SS Uric Acid	● 0.32	
Urine Uric Acid (g/dl)	● 0.277	

**Interpretation Of Laboratory Results**

Note that in the following automated interpretation the current sample is compared to the sample collected on 07/25/2004 because the urine creatinine excretion varied between the current sample and the sample collected on 07/26/2004 by an excessive amount.

Urine volume has risen but remains low (was 0.91 and now is 1.46 l/d). Low urine volume in a stone former should always be corrected if possible. A good clinical goal is 2.5 liters daily. Recheck in 6 weeks and adjust fluid intake as needed.

Borderline hypercalcaemia is now present (was 26 and now is 33 mg/dl). This can contribute to calcium oxalate stone disease. Our records do not show the presence of bowel disease. High protein diet is not a likely cause of hypercalcaemia (PCR = 0.9 g/kg/d). Low calcium diet can increase urine oxalate and should be clinically evaluated. Low oxalate diet should be prescribed. Consider diet change and repeat in 6 to 12 weeks.

Urine citrate has risen but remains low (was 247 and now is 358 mg/dl). Our records do not report that potassium citrate has been prescribed. Since urine citrate is low and SS CaP is not high consider adding



## Control Costs

- Continue focus on collections and bad debt reduction
- Optimize supply chain
- Use efficiency gains to improve patient experience





## Revenue and EPS Growth

- 10% Revenue CAGR
- 17% EPS CAGR


Revenue and EPS Growth: 2004-2008 <sup>(1)</sup> <sup>(2)</sup>



(1) Excluding the \$0.09 per diluted share impact in 2005 of restructuring and other special charges, and a non-recurring investment loss; excluding the \$0.06 per diluted share impact in 2006 of restructuring and other special charges; excluding the \$0.25 per diluted share impact in 2007 of restructuring and other special charges; excluding the \$0.44 per diluted share impact in 2008 of restructuring and other special items  
 (2) EPS, as presented, represents adjusted, non-GAAP financial measures. Diluted EPS, as reported in the Company's Annual Report were: \$2.45 in 2004; \$2.71 in 2005; \$3.24 in 2006; \$3.93 in 2007; and \$4.16 in 2008.

## Leading Returns

- Improving and leading returns
- Leading EBIT margin



## Cash Flow

- 10% OCF CAGR
- \$2.5 B+ share repurchase

**LabCorp Cash Flow: 2004-2008**



	Three Months Ended Sept 30,			Nine Months Ended Sept 30,		
	2009	2008	+/(-) %	2009	2008	+/(-) %
Revenue	\$ 1,185.1	\$ 1,135.1	4.4%	\$3,529.7	\$3,386.1	4.2%
Adjusted Operating Income	\$ 237.6	\$ 219.9	8.0%	\$ 733.0	\$ 717.2	2.2%
Operating Income Margin	20.0%	19.4%	60 bp	20.8%	21.2%	(40) bp
Adjusted EPS	\$ 1.22	\$ 1.10	10.9%	\$ 3.74	\$ 3.48	7.5%
Operating Cash Flow	\$ 246.4	\$ 194.4	26.7%	\$ 637.7	\$ 565.6	12.7%
Less: Capital Expenditures	\$ (22.7)	\$ (41.5)	-45.3%	\$ (77.1)	\$ (120.4)	-36.0%
Free Cash Flow	\$ 223.7	\$ 152.9	46.3%	\$ 560.6	\$ 445.2	25.9%

Other Financial Information  
September 30, 2009  
(\$ in million's)

	<u>Q1 09</u>	<u>Q2 09</u>	<u>Q3 09</u>	<u>YTD 2009</u>
Bad debt as a percentage of sales	5.3%	5.3%	5.3%	5.3%
Days sales outstanding	52	50	48	48
A/R coverage (Allowance for Doubtful Accts. / A/R)	19.5%	20.6%	21.9%	21.9%

## Key Points

- Critical position in health care delivery system
- Attractive market
- Strong competitive position - well positioned to gain share
- Leadership in personalized medicine
- Excellent cash flow
- Strong balance sheet



